Immunologic Factors: all 3,292 studies that test it
Page 29 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus ErythematosusCompletedNCT00482989Phase 1
- CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to TreatmentCompletedNCT00482521Phase 1
- A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for MyelosuppressionCompletedNCT00482261Phase 2
- Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00478959Phase 2
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00477815Phase 1
- Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living DonorWithdrawnNCT00476515Phase 1
- Study of Rituximab to Treat Chronic Renal Transplant RejectionCompletedNCT00476164Phase 4
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Optimizing IFN Beta - 1B DoseCompletedNCT00473213Phase 3
- A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545CompletedNCT00472758Phase 1
- Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseStatus unknownNCT00472225Phase 2
- B-Lymphocyte Immunotherapy in Islet TransplantationTerminatedNCT00468442Phase 2
- Efficacy of Islet After Kidney TransplantationCompletedNCT00468117Phase 3
- Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.CompletedNCT00466895Phase 1
- Effects of Antithymocyte Globulin in Adults With Myelodysplastic SyndromeStatus unknownNCT00466843Phase 2
- Strategies to Improve Islet SurvivalCompletedNCT00464555Phase 2
- Preventive IVIG Therapy for Congenital Heart BlockCompletedNCT00460928Early Phase 1
- CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedNCT00455897Phase 2
- High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII MelanomaWithdrawnNCT00447356Phase 3
- A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseCompletedNCT00446433Phase 2
- Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal CancerCompletedNCT00445523Phase 2
- Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's LymphomaCompletedNCT00440388Phase 2
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedNCT00436254Phase 1
- Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular LymphomaStatus unknownNCT00435955Phase 3
- Islet Transplantation in Type 1 DiabetesCompletedNCT00434811Phase 3
- Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of MyelodysplasiaStatus unknownNCT00434239Early Phase 1
- Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing SpondylitisStatus unknownNCT00432653Phase 2/3
- Effect of Intravenous Immunglobulin (IVIG) After Myocardial InfarctionCompletedNCT00430885Phase 3
- Maintenance Therapy Using Lenalidomide in MyelomaCompletedNCT00430365Phase 3
- HGS-ETR2 to Treat Children With Solid TumorsTerminatedNCT00428272Phase 1
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00428142Phase 2
- Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)CompletedNCT00427856Phase 2
- Effect of B-cell Depletion in Patients With Primary Sjögren's SyndromeCompletedNCT00426543Phase 2
- Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT00425932Phase 2
- Rituximab in Membranous NephropathyCompletedNCT00425217Phase 2/3
- Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]Status unknownNCT00424229Phase 2
- Rituximab Treatment of Graves' Dysthyroid OphthalmopathyCompletedNCT00424151Phase 1/2
- Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan PatientsCompletedNCT00422617Not applicable
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1
- Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent InfectionsCompletedNCT00417573Phase 2
- Intrathecal Rituximab in Treating Patients With Recurrent CNS LymphomaCompletedNCT00416923Phase 1
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS LymphomaCompletedNCT00416819Not applicable
- Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00415116Phase 1
- Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple MyelomaCompletedNCT00415064Phase 1
- Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic MelanomaCompletedNCT00412581Phase 1
- Thymoglobulin (ATG) Dose Finding StudyTerminatedNCT00409695Phase 1/2
- Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.CompletedNCT00407342Not applicable
- Rituximab in the Treatment of Idiopathic Membranous NephropathyCompletedNCT00405340Early Phase 1
- A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970gWithdrawnNCT00404157Phase 3
- Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00402558Phase 1
- A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13CompletedNCT00400478Phase 3
- Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
- Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaStatus unknownNCT00397800Phase 1/2
- Alefacept for Chronic Graft Versus Host DiseaseCompletedNCT00397332Phase 1/2
- Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple MyelomaCompletedNCT00396045Phase 1/2
- Safety and Efficacy of Fludarabine and Cyclophosphamide + RituximabCompletedNCT00393107Phase 2
- Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00392691Phase 1
- Does the Order in Which Vaccines Are Administered Affect Pain Response?CompletedNCT00390130Phase 4
- Rituximab Combined With Chemotherapy in Burkitt's LymphomaCompletedNCT00388193Phase 2
- A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal CancerStatus unknownNCT00385970Phase 3
- Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell TransplantationCompletedNCT00383994Phase 1
- Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple MyelomaCompletedNCT00378768Phase 2
- Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell TransplantCompletedNCT00376480Phase 1
- Open-Label,Singel Center Study of Alefacept in Patients With Atopic DermatitisCompletedNCT00376129Phase 2
- A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.CompletedNCT00376077Phase 3
- Therapy for Chronic Cold Agglutinin DiseaseCompletedNCT00373594Phase 2
- Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)CompletedNCT00372892Phase 2
- Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney RecipientsStatus unknownNCT00371904Phase 2
- Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV InfectionCompletedNCT00371878Phase 4
- Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaTerminatedNCT00367497Phase 2
- Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic LeukemiaCompletedNCT00366418Phase 1
- Rituximab Treatment in Sjogren's SyndromeCompletedNCT00363350Phase 1/2
- Alefacept for Prevention of Graft Versus Host Disease (GVHD)TerminatedNCT00361413Phase 3
- Efficacy and Safety Study of GB-0998 for Treatment of Systemic SclerosisCompletedNCT00348296Phase 3
- Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's LymphomaCompletedNCT00347971Phase 1
- Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)CompletedNCT00346684Phase 2
- Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate UveitisCompletedNCT00344253Phase 3
- Rituximab as Second Line Treatment for ITPCompletedNCT00344149Phase 3
- Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT00343447Phase 2
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT00337246Phase 2
- Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's LymphomaCompletedNCT00334438Phase 1
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.Status unknownNCT00333008Phase 2
- Combined Use of BCG and Interferon Alpha in Bladder CancerCompletedNCT00330707Phase 2/3
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1
- Study of Sargramostim in Moderately to Severely Active Crohn's DiseaseTerminatedNCT00329537Phase 2
- Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic CancerCompletedNCT00329368Phase 1
- GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaSuspendedNCT00324831Phase 3
- Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic LeukemiaCompletedNCT00324779Phase 2
- Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid TreatmentStatus unknownNCT00324467Phase 2
- Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood LymphocytesCompletedNCT00324389Phase 2
- A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's LymphomaCompletedNCT00322985Phase 2
- Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00317798Phase 1
- PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPCTerminatedNCT00313482Phase 2
- Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's LymphomaWithdrawnNCT00310128Phase 2
- Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)CompletedNCT00309881Phase 2
- Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)TerminatedNCT00307827Phase 2
- Intravenous Immunoglobulin After Relapse in VasculitisTerminatedNCT00307658Phase 3
- RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing VasculitidesCompletedNCT00307593Not applicable
- Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00306813Phase 1/2